Fig. 2: Exosomal miR-204-5p released by human T lymphocytes is decreased under inflammatory conditions.
From: Identification of novel rheumatoid arthritis-associated MiRNA-204-5p from plasma exosomes
a Schematic representation of whole blood composition including peripheral blood mononuclear cells (PBMCs), T cells and exosomes. b The expression of miR-204 in PBMCs from the RA patients (n = 28) and the healthy controls (n = 15) examined by miRNA microarray. c The expression of miR-204-5p in CD3+ T lymphocytes in the RA patients (n = 7) and the healthy controls (n = 7) examined by RT-qPCR. d Human Jurkat T lymphocytes were treated with PMA (10 ng/ml), and then, the expression of miR-204-5p was determined thereafter at the indicated time points by RT-qPCR. e Jurkat T cells were pretreated with or without cyclosporin A (CyA) at the indicated doses (20 and 100 nM) for 30 min and then incubated with PMA (10 ng/ml) for 12 h. Exosomal miR-204-5p expression released by Jurkat T cells was determined by RT-qPCR. f Cells were costimulated with CD3/CD28 antibodies (2.0 µg/ml) for 24 h. MiR-204-5p expression in Jurkat T cells and exosomal miR-204-5p expression released by Jurkat T cells were then analyzed by RT-qPCR. g MH7A cells were treated with TNF-a (50 ng/ml) for 24 h. MiR-204-5p expression in MH7A cells was analyzed by RT-qPCR. Data are presented as the mean ± SD of three independent experiments, Student’s t-test in b,c, and g, one-way ANOVA in e, f, n.s. not significant; *P < 0.05; **P < 0.01.
